Technical Analysis for INVA - Innoviva, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.79% | |
| Upper Bollinger Band Touch | Strength | 0.79% | |
| Stochastic Reached Overbought | Strength | -0.90% | |
| Upper Bollinger Band Walk | Strength | -0.90% | |
| Above Upper BB | Strength | -0.90% | |
| Overbought Stochastic | Strength | -0.90% | |
| Upper Bollinger Band Touch | Strength | -0.90% | |
| Expansion Breakout | Bullish Swing Setup | -1.39% | |
| Above Upper BB | Strength | -1.39% | |
| Gapped Up | Strength | -1.39% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 32 minutes ago |
| Possible NR7 | about 2 hours ago |
| Possible Inside Day | about 2 hours ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Innoviva, Inc. Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Glucocorticoids Antero Corticosteroid Organofluorides Respiratory Products Combination Drugs Fluticasone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.865 |
| 52 Week Low | 12.22 |
| Average Volume | 688,124 |
| 200-Day Moving Average | 14.50 |
| 50-Day Moving Average | 15.04 |
| 20-Day Moving Average | 15.36 |
| 10-Day Moving Average | 15.61 |
| Average True Range | 0.43 |
| RSI (14) | 59.68 |
| ADX | 23.57 |
| +DI | 24.88 |
| -DI | 12.39 |
| Chandelier Exit (Long, 3 ATRs) | 15.22 |
| Chandelier Exit (Short, 3 ATRs) | 15.62 |
| Upper Bollinger Bands | 16.10 |
| Lower Bollinger Band | 14.61 |
| Percent B (%b) | 0.82 |
| BandWidth | 9.72 |
| MACD Line | 0.25 |
| MACD Signal Line | 0.17 |
| MACD Histogram | 0.0789 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.65 | ||||
| Resistance 3 (R3) | 16.68 | 16.45 | 16.52 | ||
| Resistance 2 (R2) | 16.45 | 16.24 | 16.43 | 16.47 | |
| Resistance 1 (R1) | 16.14 | 16.11 | 16.03 | 16.11 | 16.42 |
| Pivot Point | 15.91 | 15.91 | 15.85 | 15.89 | 15.91 |
| Support 1 (S1) | 15.60 | 15.70 | 15.49 | 15.57 | 15.26 |
| Support 2 (S2) | 15.37 | 15.57 | 15.35 | 15.21 | |
| Support 3 (S3) | 15.06 | 15.37 | 15.17 | ||
| Support 4 (S4) | 15.03 |
